Orchestra BioMed (NASDAQ:OBIO – Get Free Report) is one of 228 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Orchestra BioMed to similar businesses based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.
Risk and Volatility
Orchestra BioMed has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s competitors have a beta of 1.11, suggesting that their average stock price is 11% more volatile than the S&P 500.
Valuation and Earnings
This table compares Orchestra BioMed and its competitors gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Orchestra BioMed | $2.76 million | -$49.12 million | -2.96 |
Orchestra BioMed Competitors | $1.05 billion | $4.23 million | -5.64 |
Profitability
This table compares Orchestra BioMed and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Orchestra BioMed | -1,779.71% | -58.32% | -41.47% |
Orchestra BioMed Competitors | -740.60% | -138.78% | -27.34% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Orchestra BioMed and its competitors, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Orchestra BioMed | 0 | 0 | 2 | 0 | 3.00 |
Orchestra BioMed Competitors | 1588 | 4288 | 8323 | 222 | 2.50 |
Orchestra BioMed presently has a consensus price target of $17.00, indicating a potential upside of 282.88%. As a group, “Surgical & medical instruments” companies have a potential upside of 30.37%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, research analysts clearly believe Orchestra BioMed is more favorable than its competitors.
Insider and Institutional Ownership
53.6% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.5% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Orchestra BioMed competitors beat Orchestra BioMed on 7 of the 13 factors compared.
Orchestra BioMed Company Profile
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.